

Management and Pharmacoeconomics of Dry Eye Disease: The Role of Cyclosporine

This supplement to *The American Journal of Managed Care* provides information on the impact of dry eye disease on managed care, current trends in the management of dry eye disease, and the emerging role of cyclosporine as a disease-modifying rather than merely palliative pharmacologic treatment.

■ Faculty

Richard G. Fiscella, BS Pharm, MPH

Clinical Professor
University of Illinois at Chicago
Chicago, Illinois

Todd D. Killian, MBA, MS

Director, Customer Marketing
Allergan, Inc
Irvine, California

Jeffrey T. Lee, PharmD, FCCP

Director, Applied Health
Outcomes
Allergan, Inc
Franklin, Tennessee

Michael A. Lemp, MD

Clinical Professor of
Ophthalmology
Georgetown and George
Washington Universities
Chief Medical Officer
OcuSense, Inc
Washington, DC

Henry D. Perry, MD

Chief, Cornea Service
Medical Director of the Lions Eye
Bank for Long Island
North Shore University Hospital
Manhasset, New York
Senior Partner, Ophthalmic
Consultants of Long Island
Rockville Centre, New York

Stephen C. Pflugfelder, MD

Professor of Ophthalmology
Baylor College of Medicine
Houston, Texas

John G. Walt, MBA

Director, Global Health Outcomes
Strategy & Research
Allergan, Inc
Irvine, California

Management and Pharmacoeconomics of Dry Eye Disease: The Role of Cyclosporine

Funding

This supplement has been supported by funding from **Allergan, Inc.**



The contents of this supplement may include information regarding the use of products that may be inconsistent with or outside the approved labeling for these products in the United States. Physicians should note that the use of these products outside current approved labeling is considered experimental and are advised to consult prescribing information for these products.